This study from the Jacksonville group reported treatment outcomes of 56 patients with de novo, nonmetastatic ACC of the head and neck treated with definitive (n = 9) or adjuvant PT (n = 47). With a median follow-up of 6.2 years, the 5-year local-regional control (LRC), disease-free survival, cause-specific survival, and overall survival rates were 88%, 85%, 89%, and 89%. The 5-year cumulative incidence of clinically significant grade ≥3 toxicity was 15%respectively. The authors concluded that PT can provide excellent disease control for ACC of the head and neck with acceptable toxicity.